tiprankstipranks
Shanghai Fosun Pharma Moves Forward with Henlius Merger
Company Announcements

Shanghai Fosun Pharma Moves Forward with Henlius Merger

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Don't Miss Our Christmas Offers:

Shanghai Fosun Pharmaceutical is progressing towards the privatization of Shanghai Henlius Biotech via a merger by absorption, having recently secured approval from China’s National Development and Reform Commission. The company is actively working with local authorities to fulfill additional pre-conditions necessary for the merger. The dispatch of the Composite Document has been delayed, with a new deadline set for May 2025.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharmaceutical Advances Henlius Merger Plans
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharma Moves Hong Kong Office
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharmaceutical Moves Forward with Henlius Merger
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App